Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

The case claims vapes are not smokable products because they don't combust and should be held to lower THC limits.

Company to Roll Out Availability of IMKELDI (imatinib) for Patients with Certain Forms of Leukemia and Other Cancers Shorla Oncology ('Shorla'), a U.S.-Ireland specialty pharmaceutical company, ...

The arrival of the MG Cyberster marks a significant moment in ... while an overnight top up at home (from 10-100 per cent), via a 7kW wallbox, requires 12.5 hours. Dramatic design flourishes ...

Rats were anaesthetised with intraperitoneal injection of ketamine (100 mg/kg)/xylazine (5 mg/kg) for these experiments ... To generate the aerosol and mainstream smoke, we used a manual syringe pump ...

LAKE ZURICH, IL, USA I March 03, 2025 I Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality ...

FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous ...

Otulfi will be available in the U.S. in the following presentations: a 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringe for injection ... present in more than 100 countries, Fresenius ...